This study assessed the Hr QoL (Health related Quality of life) of subjects with mild to moderate AD, who received ARICEPT under usual clinical practice.
This non-interventional study enrolled patients with mild to moderate dementia of the Alzheimer's type, who have been prescribed treatment with ARICEPT under usual clinical practice.
Study Type
OBSERVATIONAL
Enrollment
628
Number of Participants for Change From Baseline for Clinical Global Impressions of Improvement (CGI-I) at Week 12
CGI-I is a 7-point physician rated scale ranging from very much improved to very much worse.
Time frame: Baseline, Week 12.
Number of Participants for Change From Baseline for the Caregiver's Assessment of Improvement at Week 12
The caregiver's assessment improvement was a 5-point rated scale ranging from much improved to much worse to the question 'compared to the severity of your relative's condition at baseline, how much do you feel it has changed?'.
Time frame: Baseline, Week 12.
Change From Baseline in the Participant's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12
QoL-AD was comprised of 13 individual items, each measured on a 4-point Likert scale (ranging from 1 \[poor\] to 4 \[excellent\]). Overall QoL-AD score was the sum of the scores for the 13 individual items and ranged from 13 to 52, with higher scores indicating a higher health related quality of life.
Time frame: Baseline, Week 12.
Change From Baseline in the Caregiver's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12
QoL-AD was comprised of 13 individual items, each measured on a 4-point Likert scale (ranging from 1 \[poor\] to 4 \[excellent\]). Overall QoL-AD score was the sum of the scores for the 13 individual items and ranged from 13 to 52, with higher scores indicating a higher health related quality of life.
Time frame: Baseline, Week 12.
Change in ARICEPT Dosing: Number of Participants for Time to First ARICEPT Dose Escalation
The starting dose of ARICPET was 5 mg once daily (QD), which could be increased to 10 mg QD during the study.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University Hospital of Alexandroupolis Dimokritio
Alexandroupoli, Thrace, Greece
General Hospital of Arta
Arta, Greece
NIMITS (Geriatric Department)
Athens, Greece
NIMITS Geriatric Department
Athens, Greece
General Hospital of Athens Laikon Dementia Department
Athens, Greece
Naval Hospital, Dementia Department
Athens, Greece
General State Hospital "G. Genimatas", Neurology Department
Athens, Greece
ATTIKON University General Hospital (Dementia Department)
Athens, Greece
Psychiatric Hospital of Attica Dromokaiteio, Psychiatric Department
Athens, Greece
1st IKA Hospital Neurology Clinic
Athens, Greece
...and 19 more locations
Time frame: Baseline to Week 12.
Change in ARICEPT Dosing: Number of Participants at Each Final Dose of ARICEPT
Time frame: Week 12.
Number of Participants for the Physician's Assessment of Tolerance to ARICEPT at Week 12
The physician rated tolerance to ARICEPT as very good, good, adequate, unsatisfactory, or unevaluable.
Time frame: Baseline to Week 12.